4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Free Cash Flow data on file, last reported at -$68.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 42.23% year-over-year to -$68.1 million in Q1 2026; TTM through Mar 2026 was -$134.2 million, a 14.21% increase from a year earlier, with the FY2025 full-year figure at -$114.0 million, up 17.61% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$68.1 million, down from $24.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for FDMT reached as high as $24.2 million in Q4 2025 and fell as low as -$68.1 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$28.4 million across 5 years, with a median of -$29.8 million in 2024.
• Across the five-year window, Free Cash Flow slumped 911.65% in 2024 and soared 151.76% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$21.8 million in 2022, then decreased by 4.08% to -$22.7 million in 2023, then slumped by 106.57% to -$46.8 million in 2024, then soared by 151.76% to $24.2 million in 2025, then tumbled by 381.16% to -$68.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$68.1 million in Q1 2026, $24.2 million in Q4 2025, and -$46.4 million in Q3 2025.